Working… Menu

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00165672
Recruitment Status : Completed
First Posted : September 14, 2005
Results First Posted : October 5, 2011
Last Update Posted : October 5, 2011
Eisai Limited
Information provided by:
Eisai Inc.

Brief Summary:
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).

Condition or disease Intervention/treatment Phase
Non-erosive Gastroesophageal Reflux Disease Drug: RABEPRAZOLE SODIUM Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Study Start Date : May 2005
Actual Primary Completion Date : October 2005
Actual Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arm Intervention/treatment
Experimental: 1 Drug: RABEPRAZOLE SODIUM
rabeprazole sodium 5 mg: once daily orally for 4 weeks

Experimental: 2 Drug: RABEPRAZOLE SODIUM
rabeprazole sodium 10 mg: once daily orally for 4 weeks

Primary Outcome Measures :
  1. The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring). [ Time Frame: Baseline and 4 weeks ]
    Mean and standard deviation of percent time pH<4.0 on 24 hour esophageal pH monitoring.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The patients to be included will be outpatients who meet all of the following criteria. No specific gender is asked.

<For the observation period>

  1. Patients who have "heartburn" 2 days a week or more during consecutive 3 weeks* prior to pre-observation screening. *If a day of screening and a day of starting observation (date of registration) are different, heartburn must continuously be present during the in-between period.
  2. Patients who meet both 1) and 2) below;

1) The symptom is a burning sensation arising from the stomach or the lower chest.

2) The symptom tends to appear frequently or is aggravated after eating, when bending a body forward, and/or when pressing on the abdomen.

3. Patients categorized in "grade M" (discoloring type: minimal change) according to the Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.

4. Patients who are 20 years old or older at the time of obtaining consent.

5. Patients who are informed of the objective and details of this study and give written consent for study entry.

<For the treatment period>

  1. Patients who have "heartburn" 2 days a week or more during 7 days until the treatment period (during the observation period).
  2. Patients with "heartburn diary" that is completely filled out during 7 days until the treatment period (during the observation period). If the observation period is 8 days or longer, those with a heartburn diary of which entries are fulfilled 80% or more during the observation period.
  3. Patients with 80% or better drug compliance for antacids during the observation period.
  4. Patients whose percentage of time showing pH<4.0 (% time pH<4.0) is not 0%* during the 24-hour esophageal pH monitoring at the end of observation period (at the beginning of treatment period). *If parameters calculated from analytical program show 0.0% after round-off, this patient cannot be entered into the treatment period.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Patients who cannot keep adequate entries of a heartburn diary by themselves.
  2. Patients who strongly complain "feeling of heavy stomach" and/or "abdominal bloating."
  3. Patients who have a complication or history of psychiatric or psychosomatic disease (e.g., manic-depressive psychosis, obsessive-compulsive neurosis, or others) or those who are on an antidepressant or anti-anxiety agent (accepted if only for a hypnotic treatment).
  4. Patients who have undergone Helicobacter pylori eradication therapy, and less than 6 months* have elapsed from the end of H. pylori eradication therapy to the beginning of the observation period. *: The same day 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  5. Patients with open gastric or duodenal ulcer.
  6. Patients with acute gastritis.
  7. Patients with a history of any surgical intervention that affect peptic secretion (e.g., upper gastrointestinal tract resection and/or vagotomy).
  8. Patients with Barrett's esophagus, esophageal stenosis, or pyloric stenosis.
  9. Patients with scleroderma.
  10. Patients with a history or complication of angina pectoris.
  11. Patients who work at night (working for a night-shift).
  12. Patients who received proton pump inhibitors (PPIs) within 3 weeks prior to pre-observation screening.
  13. Patients who need non steroidal anti-inflammatory drugs (NSAIDs) (except topical preparations), steroids (except topical preparations), and/or aspirin treatment every day.
  14. Patients receiving dialysis therapy.
  15. Patients with a serious complication such as cardiovascular disease (myocardial infarction, etc.), hematological disorder (e.g, aplastic anemia), renal disease (e.g., acute or chronic renal failure), hepatic disease (e.g., cirrhosis), or malignant tumor.
  16. Patients with known hypersensitivity to antacids or PPIs.
  17. Patients who are pregnant or those with childbearing potential, or those who wish to become pregnant or are lactating during the study period.
  18. Patients receiving another investigational drug or those who received another investigational drug within 6 months prior to pre-observation screening* *: Registration is allowed on the same day of 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  19. Patients who are judged to be ineligible for the study entry by the investigator or subinvestigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00165672

Layout table for location information
Nagoya, Aichi-Prefecture, Japan, 467-0001
Fukuoka, Fukuoka-Prefecture, Japan, 810-0001
Fukuoka, Fukuoka-Prefecture, Japan, 811-0213
Yukuhashi, Fukuoka-Prefecture, Japan, 824-0026
Hiroshima, Hiroshima-Prefecture, Japan, 734-0037
Osaka, Osaka-Prefecture, Japan, 530-0012
Osaka, Osaka-Prefecture, Japan, 545-0051
Saga, Saga-Prefecture, Japan, 849-0937
Otsu, Shiga-Prefecture, Japan, 520-2121
Izumo, Shimane-Prefecture, Japan, 693-0021
Bunkyo-ku, Tokyo, Japan, 113-0022
Shinjuku-ku, Tokyo, Japan, 162-0052
Ube, Yamaguchi-Prefecture, Japan, 755-0046
Sponsors and Collaborators
Eisai Inc.
Eisai Limited
Layout table for investigator information
Study Director: Nobuyuki Sugisaki Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center
Layout table for additonal information
Responsible Party: Nobuyuki Sugisaki, Eisai Co., Ltd. Identifier: NCT00165672    
Other Study ID Numbers: E3810-J081-462
First Posted: September 14, 2005    Key Record Dates
Results First Posted: October 5, 2011
Last Update Posted: October 5, 2011
Last Verified: August 2010
Keywords provided by Eisai Inc.:
24-hour esophageal pH monitoring
non-erosive gastroesophageal reflux disease
proton pump inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophagitis, Peptic
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Stomach Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action